IMVT Immunovant, Inc.
Q4 2025 10-Q
Filed: Feb 6, 2026Period ending Dec 31, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Immunovant, Inc. (IMVT) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 6, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ4 2025 10-Q
Risk Factors
- • New risk: Potential HanAll Agreement dispute triggered by ongoing rights return discussions for batoclimab
- • Updated risk: Clinical trial timing for IMVT-1402 now delayed, with first top-line data expected in 2027 vs prior undefined timeline
Quarterly Financial SummaryXBRL
Net Income
-$111M
▲ +0.4% YoY▲ +12.5% QoQ
ROE
-11.2%
▲ +2029bp YoY
Total Assets
$1.1B
▲ +150.0% YoY
EPS (Diluted)
$-0.61
▲ +19.7% YoY▲ +15.3% QoQ
Operating Cash Flow
-$92M
▲ +8.0% YoY▲ +9.9% QoQ
Source: XBRL data from Immunovant, Inc. Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Immunovant, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.